Alphabet kickstarts new AI drug discovery outfit with lessons learned from DeepMind protein breakthroughs
Last summer marked a major breakthrough in drug discovery when DeepMind, a predictive modeling startup from Google parent company Alphabet, offered the most accurate picture yet of the “protein folding” problem. The Alphabet team is now propping up a unit focused solely on drug discovery, and it will look to leverage lessons learned from DeepMind’s example.
Alphabet has launched Isomorphic Labs, a London-based drug discovery startup leveraging the company’s AI and machine learning work, and lessons from DeepMind’s AlphaFold breakthroughs, CEO Demis Hassabis said in a blog post Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
